Using data science to identify aggressive cancer types and predict survival in head and neck cancer without HPV.
Official title: Data science approaches to classify aggressive tissue phenotypes and predict disease-free survival in HPV-negative head and neck squamous cell carcinoma (HNSCC)
Funded at Rutgers Biomedical and Health Sciences · NIH-11114716 · Data updated 2026-11-12
This study is looking at a type of throat and neck cancer that isn't caused by HPV, and it aims to use new data techniques to better understand how different tissue types affect survival, which could help doctors make more personalized treatment choices for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | April 7, 2025 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $168,610 |
| NIH project number | 1K08DE034852-01 |
| Project ID | NIH-11114716 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with HPV-negative head and neck squamous cell carcinoma.
✕Less likely to help
Patients with HPV-positive head and neck cancers or those with other unrelated cancers may not benefit from this research.
What this research studies
This research focuses on head and neck squamous cell carcinoma (HNSCC) that is negative for human papillomavirus (HPV). It aims to use advanced data science techniques to classify aggressive tissue types and understand their impact on patient survival. By analyzing genetic differences and histopathologic factors, the study seeks to improve the accuracy of prognostic factors beyond traditional staging methods. This could lead to better treatment decisions tailored to individual patient needs.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of disease outcomes and personalized treatment strategies for patients with HPV-negative head and neck cancer.
How similar studies have gone: Other research has shown promise in using data science and molecular analysis to improve cancer prognostics, indicating that this approach could be effective.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Liu, Yingci — Rutgers Biomedical and Health Sciences
- Study coordinator: Liu, Yingci
Related research
Other NIH-funded projects on the same topics.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Hypoxia and metabolism as targets to improve immunotherapy in head and neck cancer
This grant tests new combinations of metabolic drugs with immunotherapy to help people with head and neck cancer respond better to treatment.
-
Targeting low oxygen and abnormal metabolism to help immunotherapy work better in head and neck cancer
This research tests whether changing tumor oxygen levels and metabolism can help immunotherapy work better for people with recurrent or metastatic head and neck cancer.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.